
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Published on December 27, 2024
regarding its ability to fund ongoing operations into 2025, future expenses, capital requirements, and need for additional financing in the
Other news
